市場調査レポート
商品コード
1066591

先進ドラッグデリバリーシステムの世界市場(2022年~2026年)

Global Advanced Drug Delivery Systems Market 2022-2026

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
先進ドラッグデリバリーシステムの世界市場(2022年~2026年)
出版日: 2022年03月15日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の先進ドラッグデリバリーシステムの市場規模は、2022年~2026年の間に917億9,000万米ドルの増加が見込まれ、予測期間中のCAGRで7.41%の緩やかな成長が予測されています。市場を牽引しているのは、慢性疾患の増加、ドラッグデリバリーの研究開発への投資増などです。

当レポートでは、世界の先進ドラッグデリバリーシステム市場について調査分析し、全体分析、市場規模・予測、動向、成長促進要因、課題、および約25社を網羅したベンダー分析を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

第3章 市場規模

  • 市場定義
  • 市場のセグメント分析
  • 市場規模:2021年
  • 市場の見通し:2021年~2026年の予測

第4章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者がもたらす脅威
  • 代替品がもたらす脅威
  • ライバル業者がもたらす脅威
  • 市況

第5章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • 比較:タイプ別
  • 経口 - 市場規模と予測(2021年~2026年)
  • 注射と吸入 - 市場規模と予測(2021年~2026年)
  • 経皮 - 市場規模と予測(2021年~2026年)
  • 担体ベース - 市場規模と予測(2021年~2026年)
  • その他 - 市場規模と予測(2021年~2026年)
  • 市場機会:タイプ別

第6章 顧客情勢

  • 概要

第7章 地域別情勢

  • 地域セグメンテーション
  • 地域比較 - 市場規模と予測(
  • 北米 - 市場規模と予測(2021年~2026年)
  • 欧州 - 市場規模と予測(2021年~2026年)
  • アジア - 市場規模と予測(2021年~2026年)
  • その他の地域 - 市場規模と予測(2021年~2026年)
  • 主要国
  • 市場機会:地域情勢別

第8章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 市場動向

第9章 ベンダー情勢

  • 概要
  • 混乱の状況

第10章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • 3M Co.
  • Alkermes Public Co. Ltd.
  • Antares Pharma Inc.
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Endo International Plc
  • NanoPass Technologies Ltd.
  • Nektar Therapeutics
  • Perrigo Co. Plc
  • Teva Pharmaceutical Industries Ltd.

第11章 付録

目次
Product Code: IRTNTR72271

Technavio has been monitoring the advanced drug delivery systems market and it is poised to grow by $ 91.79 bn during 2022-2026 decelerating at a CAGR of 7.41% during the forecast period. Our report on advanced drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising chronic diseases and rising investment in research and development of drug delivery.

The advanced drug delivery systems market analysis includes the type segment and geographic landscape.

Technavio's advanced drug delivery systems market is segmented as below:

By Type

  • Oral
  • Injection and inhalation
  • Transdermal
  • Carrier-based
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising healthcare expenditure globallyas one of the prime reasons driving the advanced drug delivery systems market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on advanced drug delivery systems market covers the following areas:

  • Advanced drug delivery systems market sizing
  • Advanced drug delivery systems market forecast
  • Advanced drug delivery systems market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading advanced drug delivery systems market vendors that include 3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. Also, the advanced drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary

  • 1.1 Market Overview
  • Exhibit 01: Key Finding 1
  • Exhibit 02: Key Finding 2
  • Exhibit 03: Key Finding 3
  • Exhibit 04: Key Finding 5
  • Exhibit 05: Key Finding 6
  • Exhibit 06: Key Finding 7
  • Exhibit 07: Key Finding 8

2. Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 08: Parent market
  • Exhibit 09: Market Characteristics
  • 2.2 Value chain analysis
  • Exhibit 10: Value chain analysis: Life Sciences Tools and Services
    • 2.2.1 Research and development
    • 2.2.2 Inputs
    • 2.2.3 Production
    • 2.2.4 Distribution
    • 2.2.5 Marketing and sales
    • 2.2.6 Post-sales and services
    • 2.2.7 Industry innovations

3. Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021 - 2026
    • 3.4.1 Estimating growth rates for emerging and high-growth markets
    • 3.4.2 Estimating growth rates for mature markets
  • Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ billion)
  • Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

  • 4.1 Five Forces Summary
  • Exhibit 15: Five forces analysis 2021 & 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 16: Bargaining power of buyers
  • 4.3 Bargaining power of suppliers
  • Exhibit 17: Bargaining power of suppliers
  • 4.4 Threat of new entrants
  • Exhibit 18: Threat of new entrants
  • 4.5 Threat of substitutes
  • Exhibit 19: Threat of substitutes
  • 4.6 Threat of rivalry
  • Exhibit 20: Threat of rivalry
  • 4.7 Market condition
  • Exhibit 21: Market condition - Five forces 2021

5. Market Segmentation by Type

  • 5.1 Market segments
    • The segments covered in this chapter are:
  • o Oral
  • o Injection and inhalation
  • o Transdermal
  • o Carrier-based
  • o Others
  • Exhibit 22: Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Type
  • Exhibit 23: Comparison by Type
  • 5.3 Oral - Market size and forecast 2021-2026
  • Exhibit 24: Oral - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 25: Oral - Year-over-year growth 2021-2026 (%)
  • 5.4 Injection and inhalation - Market size and forecast 2021-2026
  • Exhibit 26: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 27: Injection and inhalation - Year-over-year growth 2021-2026 (%)
  • 5.5 Transdermal - Market size and forecast 2021-2026
  • Exhibit 28: Transdermal - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 29: Transdermal - Year-over-year growth 2021-2026 (%)
  • 5.6 Carrier-based - Market size and forecast 2021-2026
  • Exhibit 30: Carrier-based - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 31: Carrier-based - Year-over-year growth 2021-2026 (%)
  • 5.7 Others - Market size and forecast 2021-2026
  • Exhibit 32: Others - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 33: Others - Year-over-year growth 2021-2026 (%)
  • 5.8 Market opportunity by Type
  • Exhibit 34: Market opportunity by Type

6. Customer landscape

  • 6.1 Overview
  • Exhibit 35: Customer landscape

7. Geographic Landscape

  • 7.1 Geographic segmentation
    • The regions covered in the report are:
  • o North America
  • o Europe
  • o Asia
  • o ROW
  • Exhibit 36: Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 37: Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 38: North America - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 39: North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 40: Europe - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 41: Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 42: Asia - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 43: Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 ROW - Market size and forecast 2021-2026
  • Exhibit 44: ROW - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 45: ROW - Year-over-year growth 2021-2026 (%)
  • 7.7 Key leading countries
  • Exhibit 46: Key leading countries
  • 7.9 Market opportunity By Geographical Landscape
  • Exhibit 47: Market opportunity By Geographical Landscape ($ billion)

8. Drivers, Challenges, and Trends

  • 8.1 Market drivers
    • 8.1.1 Rising chronic diseases
    • 8.1.2 Rising investment in research and development of drug delivery
    • 8.1.3 Rising healthcare expenditure globally
  • 8.2 Market challenges
    • 8.2.1 Presence of stringent regulations
    • 8.2.2 Poor healthcare infrastructure in underdeveloped or developing countries
    • 8.2.3 Biocompatibility and acceptability with human body
  • Exhibit 48: Impact of drivers and challenges
  • 8.3 Market trends
    • 8.3.1 Covid-19 pandemic to create multiple opportunities in the market
    • 8.3.2 Introduction of targeted drug delivery system
    • 8.3.3 Reduced side effects

9. Vendor Landscape

  • 9.1 Overview
  • Exhibit 49: Vendor landscape
  • 9.2 Landscape disruption
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Industry risks

10. Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 52: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 53: Market positioning of vendors
  • 10.3 3M Co.
  • Exhibit 54: 3M Co. - Overview
  • Exhibit 55: 3M Co. - Business segments
  • Exhibit 56: 3M Co. - Key offerings
  • Exhibit 57: 3M Co. - Segment focus
  • 10.4 Alkermes Public Co. Ltd.
  • Exhibit 58: Alkermes Public Co. Ltd. - Overview
  • Exhibit 59: Alkermes Public Co. Ltd. - Business segments
  • Exhibit 60: Alkermes Public Co. Ltd. - Key news
  • Exhibit 61: Alkermes Public Co. Ltd. - Key offerings
  • 10.5 Antares Pharma Inc.
  • Exhibit 62: Antares Pharma Inc. - Overview
  • Exhibit 63: Antares Pharma Inc. - Business segments
  • Exhibit 64: Antares Pharma Inc. - Key news
  • Exhibit 65: Antares Pharma Inc. - Key offerings
  • 10.6 Baxter International Inc.
  • Exhibit 66: Baxter International Inc. - Overview
  • Exhibit 67: Baxter International Inc. - Business segments
  • Exhibit 68: Baxter International Inc. - Key offerings
  • Exhibit 69: Baxter International Inc. - Segment focus
  • 10.7 Becton Dickinson and Co.
  • Exhibit 70: Becton Dickinson and Co. - Overview
  • Exhibit 71: Becton Dickinson and Co. - Business segments
  • Exhibit 72: Becton Dickinson and Co. - Key offerings
  • Exhibit 73: Becton Dickinson and Co. - Segment focus
  • 10.8 Endo International Plc
  • Exhibit 74: Endo International Plc - Overview
  • Exhibit 75: Endo International Plc - Business segments
  • Exhibit 76: Endo International Plc. - Key news
  • Exhibit 77: Endo International Plc - Key offerings
  • Exhibit 78: Endo International Plc - Segment focus
  • 10.9 NanoPass Technologies Ltd.
  • Exhibit 79: NanoPass Technologies Ltd. - Overview
  • Exhibit 80: NanoPass Technologies Ltd. - Product and service
  • Exhibit 81: NanoPass Technologies Ltd. - Key offerings
  • 10.10 Nektar Therapeutics
  • Exhibit 82: Nektar Therapeutics - Overview
  • Exhibit 83: Nektar Therapeutics - Product and service
  • Exhibit 84: Nektar Therapeutics - Key offerings
  • 10.11 Perrigo Co. Plc
  • Exhibit 85: Perrigo Co. Plc - Overview
  • Exhibit 86: Perrigo Co. Plc - Business segments
  • Exhibit 87: Perrigo Co. Plc - Key offerings
  • Exhibit 88: Perrigo Co. Plc - Segment focus
  • 10.12 Teva Pharmaceutical Industries Ltd.
  • Exhibit 89: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 90: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 91: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 92: Teva Pharmaceutical Industries Ltd. - Segment focus

11. Appendix

  • 11.1 Scope of the report
    • 11.1.1 Market definition
    • 11.1.2 Objective
    • 11.1.3 Notes and caveats
  • 11.2 Currency conversion rates for US$
  • Exhibit 93: Currency conversion rates for US$
  • 11.3 Research Methodology
  • Exhibit 94: Research Methodology
  • Exhibit 95: Validation techniques employed for market sizing
  • Exhibit 96: Information sources
  • 11.4 List of abbreviations
  • Exhibit 97: List of abbreviations

Exhibits

  • Exhibits1: Key Finding 1
  • Exhibits2: Key Finding 2
  • Exhibits3: Key Finding 3
  • Exhibits4: Key Finding 5
  • Exhibits5: Key Finding 6
  • Exhibits6: Key Finding 7
  • Exhibits7: Key Finding 8
  • Exhibits8: Parent market
  • Exhibits9: Market characteristics
  • Exhibits10: Offerings of vendors included in the market definition
  • Exhibits11: Market segments
  • Exhibits12: Global - Market size and forecast 2021 - 2026 ($ billion)
  • Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
  • Exhibits14: Five forces analysis 2021 & 2026
  • Exhibits15: Bargaining power of buyers
  • Exhibits16: Bargaining power of suppliers
  • Exhibits17: Threat of new entrants
  • Exhibits18: Threat of substitutes
  • Exhibits19: Threat of rivalry
  • Exhibits20: Market condition - Five forces 2021
  • Exhibits21: Type - Market share 2021-2026 (%)
  • Exhibits22: Comparison by Type
  • Exhibits23: Oral - Market size and forecast 2021-2026 ($ billion)
  • Exhibits24: Oral - Year-over-year growth 2021-2026 (%)
  • Exhibits25: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
  • Exhibits26: Injection and inhalation - Year-over-year growth 2021-2026 (%)
  • Exhibits27: Transdermal - Market size and forecast 2021-2026 ($ billion)
  • Exhibits28: Transdermal - Year-over-year growth 2021-2026 (%)
  • Exhibits29: Carrier-based - Market size and forecast 2021-2026 ($ billion)
  • Exhibits30: Carrier-based - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Others - Market size and forecast 2021-2026 ($ billion)
  • Exhibits32: Others - Year-over-year growth 2021-2026 (%)
  • Exhibits33: Market opportunity by Type
  • Exhibits34: Customer landscape
  • Exhibits35: Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits36: Geographic comparison
  • Exhibits37: North America - Market size and forecast 2021-2026 ($ billion)
  • Exhibits38: North America - Year-over-year growth 2021-2026 (%)
  • Exhibits39: Europe - Market size and forecast 2021-2026 ($ billion)
  • Exhibits40: Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits41: Asia - Market size and forecast 2021-2026 ($ billion)
  • Exhibits42: Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits43: ROW - Market size and forecast 2021-2026 ($ billion)
  • Exhibits44: ROW - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Key leading countries
  • Exhibits46: Market opportunity By Geographical Landscape ($ billion)
  • Exhibits47: Impact of drivers and challenges
  • Exhibits48: Vendor landscape
  • Exhibits49: Landscape disruption
  • Exhibits50: Industry risks
  • Exhibits51: Vendors covered
  • Exhibits52: Market positioning of vendors
  • Exhibits53: 3M Co. - Overview
  • Exhibits54: 3M Co. - Business segments
  • Exhibits55: 3M Co. - Key offerings
  • Exhibits56: 3M Co. - Key customers
  • Exhibits57: 3M Co. - Segment focus
  • Exhibits58: Alkermes Public Co. Ltd. - Overview
  • Exhibits59: Alkermes Public Co. Ltd. - Business segments
  • Exhibits60: Alkermes Public Co. Ltd. - Key offerings
  • Exhibits61: Alkermes Public Co. Ltd. - Key customers
  • Exhibits62: Alkermes Public Co. Ltd. - Segment focus
  • Exhibits63: Antares Pharma Inc. - Overview
  • Exhibits64: Antares Pharma Inc. - Business segments
  • Exhibits65: Antares Pharma Inc. - Key offerings
  • Exhibits66: Antares Pharma Inc. - Key customers
  • Exhibits67: Antares Pharma Inc. - Segment focus
  • Exhibits68: Baxter International Inc. - Overview
  • Exhibits69: Baxter International Inc. - Business segments
  • Exhibits70: Baxter International Inc. - Key offerings
  • Exhibits71: Baxter International Inc. - Key customers
  • Exhibits72: Baxter International Inc. - Segment focus
  • Exhibits73: Becton Dickinson and Co. - Overview
  • Exhibits74: Becton Dickinson and Co. - Business segments
  • Exhibits75: Becton Dickinson and Co. - Key offerings
  • Exhibits76: Becton Dickinson and Co. - Key customers
  • Exhibits77: Becton Dickinson and Co. - Segment focus
  • Exhibits78: Endo International Plc - Overview
  • Exhibits79: Endo International Plc - Business segments
  • Exhibits80: Endo International Plc - Key offerings
  • Exhibits81: Endo International Plc - Key customers
  • Exhibits82: Endo International Plc - Segment focus
  • Exhibits83: NanoPass Technologies Ltd. - Overview
  • Exhibits84: NanoPass Technologies Ltd. - Product and service
  • Exhibits85: NanoPass Technologies Ltd. - Key offerings
  • Exhibits86: NanoPass Technologies Ltd. - Key customers
  • Exhibits87: NanoPass Technologies Ltd. - Segment focus
  • Exhibits88: Nektar Therapeutics - Overview
  • Exhibits89: Nektar Therapeutics - Product and service
  • Exhibits90: Nektar Therapeutics - Key offerings
  • Exhibits91: Nektar Therapeutics - Key customers
  • Exhibits92: Nektar Therapeutics - Segment focus
  • Exhibits93: Perrigo Co. Plc - Overview
  • Exhibits94: Perrigo Co. Plc - Business segments
  • Exhibits95: Perrigo Co. Plc - Key offerings
  • Exhibits96: Perrigo Co. Plc - Key customers
  • Exhibits97: Perrigo Co. Plc - Segment focus
  • Exhibits98: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits99: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits100: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits101: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibits102: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits103: Currency conversion rates for US$
  • Exhibits104: Research Methodology
  • Exhibits105: Validation techniques employed for market sizing
  • Exhibits106: Information sources
  • Exhibits107: List of abbreviations